Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Phthisis Diagnostics Announces First International Distribution Agreement in Asia

Published: Friday, August 03, 2012
Last Updated: Friday, August 03, 2012
Bookmark and Share
Simple and cost-efficient molecular products make their way to India.

Phthisis Diagnostics, Inc. has announced the signing of a distribution agreement for international sales in India, its first in the Asian market.  The contract follows the company’s first international distribution agreement announced in May for sales throughout Latin America.

Genetix Biotech Asia, Ltd., located in New Delhi represents world leading companies that supply molecular biology, genomics, proteomics, immunology, and cell culture laboratories.

Genetix will handle the entire Phthisis Diagnostics product line, including those items being introduced to the market now and those in development. Phthisis currently offers the E-Sphere® Simple NA Kit for easily and quickly extracting nucleic acids from various types of samples.  Future products will include molecular diagnostics for parasites and fungi, as well as molecular standards for improved laboratory quality control.

Phthisis Diagnostics President and Chief Science Officer Crystal Icenhour, PhD, commented, “We are excited to extend our marketing into Asia with this agreement and are looking forward to continuing to expand our distribution network.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phthisis Diagnostics Announces Second Round of Funding
With their first product already in the international marketplace and a second just launched, Phthisis Diagnostics has announced a successful second round of angel funding.
Thursday, July 12, 2012
Phthisis Diagnostics Announces First International Distribution Agreement
Simple and cost-efficient molecular products make their way into Latin America.
Friday, May 25, 2012
Phthisis Diagnostics Welcomes New Sales Director and Controller
Appointment of Betty Polk and Robert Owen to Company’s management team.
Monday, May 14, 2012
Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos